Stock PRTC PURETECH HEALTH PLC
Add to a list
To use this feature you must be a member
Log inSign up

News PureTech Health plc

Equities

PRTC

GB00BY2Z0H74

Market Closed - London S.E.
Other stock markets
 11:35:12 2024-04-25 am EDT 		5-day change 1st Jan Change
212.5 GBX 0.00% Intraday chart for PureTech Health plc +2.41% +9.42%
Apr. 25 Miner Anglo American reviews takeover bid from rival BHP AN
Apr. 25 Miner Anglo American eyes rival BHP takeover AN

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
PureTech Health : Proxy Form for 2024 AGM
PU
PureTech Health : Notice of Meeting for 2024 AGM
PU
PureTech Announces Annual Results for Year Ended December 31, 2023
BU
PureTech touts "momentum" as grants shrivel but annual loss narrows
AN
Miner Anglo American reviews takeover bid from rival BHP
AN
Miner Anglo American eyes rival BHP takeover
AN
Correction: Earnings Flash (PRTC.L) PURETECH HEALTH Posts FY23 Loss $-0.24
MT
Earnings Flash (PRTC.L) PURETECH HEALTH Reports FY23 Revenue $3.3M
MT
Earnings Flash (PRTC.L) PURETECH HEALTH Posts FY24 Loss $-0.24
MT
PureTech Health plc Reports Earnings Results for the Full Year Ended December 31, 2023
CI
PureTech Health plc - Notice of Results
AQ
PureTech Health: Notice of Results
BU
PureTech Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 in Idiopathic Pulmonary Fibrosis
AQ
EARNINGS AND TRADING: J Smart boosts revenue, Tertiary starts drilling
AN
PureTech Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 (Deupirfenidone) in Idiopathic Pulmonary Fibrosis
BU
PureTech Health plc Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 (Deupirfenidone) in Idiopathic Pulmonary Fibrosis
CI
US FDA hands fast track to PureTech head and neck cancer treatment
AN
PureTech Receives FDA Fast Track Designation for LYT-200 in Head and Neck Cancers
BU
PureTech Health plc Receives FDA Fast Track Designation for LYT-200 in Head and Neck Cancers
CI
Seaport Therapeutics Launches with $100 Million Oversubscribed Series a Financing Round to Advance Novel Neuropsychiatric Medicines
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PRTC Stock
  4. News PureTech Health plc